Benign Prostatic Hyperplasia - Pipeline Review, Q4 2010
- Published: December 2010
- Your are here:
- Home
- Categories
- Pharmaceuticals and Healthcare
- Pharmaceuticals
- Oncology
R&D Trends: Benign Prostatic Hyperplasia – Small Pipeline which Lacks Promise
R&D Trends: Benign Prostatic Hyperplasia – Small Pipeline which Lacks Promise
- Published: April 2012
- Region: World
- 31 Pages
- Datamonitor
FEATURED COMPANIES
- Dendreon Corporation
- GlaxoSmithKline Plc
- Hutchison 3G UK Limited
- MORE
Review of key trends in the development of new benign prostatic hyperplasia drugs across the seven major markets. Includes analyses of clinical trial design, target product profile, innovative early-stage projects, and future treatment developments.
New therapies have entered the benign prostatic hyperplasia (BPH) drug market since Datamonitor reviewed the market in 2009, including Rapaflo (silodosin; Recordati) and Duodart/Jalyn (dutasteride and tamsulosin; GlaxoSmithKline). Meanwhile, the failure of AEterna Zentaris's cetrorelix to meet Phase III efficacy endpoints signals the end of gonadotropin-releasing hormones being approved for BPH.
Scope
- Understand key dynamics in the R&D pipeline for new BPH therapies.
- Support R&D decision-making by understanding the competitive dynamics of the pipeline.
- Benchmark pipeline candidates using the target product profile identified by Datamonitor.
- Access Datamonitor's prediction of how the treatment landscape may change in the next 20 years.
Highlights
- Datamonitor identified 18 drugs in clinical development for BPH, with orally delivered candidates accounting for 43% of the
READ MORE >
OVERVIEW
- Catalyst
- Summary
EXECUTIVE SUMMARY
- Strategic scoping and focus
- Datamonitor key findings
- Related reports
CLINICAL PIPELINE OVERVIEW
- The benign prostatic hyperplasia pipeline remains lackluster
- Mechanism of action Despite failures, disease-modifying products continue to account for the largest single proportion of the pipeline
- Symptomatic relief agents
- Disease-modifying agents
- Late-stage development compounds recently discontinued
TARGET PRODUCT PROFILE Symptomatic relief - tamsulosin Flomax (tamsulosin; Astellas/Boehringer Ingelheim)
- Disease-modifying - Avodart (dutasteride; GlaxoSmithKline) Key clinical trials
- Target product profile versus current level of attainment
CLINICAL TRIAL DESIGN IN BENIGN PROSTATIC HYPERPLASIA
- Clinical trials Recruitment criteria
- Primary endpoints
- Secondary endpoints
INNOVATIVE EARLY-STAGE APPROACHES LS11 (talaporfin sodium)
- Mechanism of action - a light-activated drug to provide localized drug action
- Clinical studies have begun
THE FUTURE OF TREATMENT IN BENIGN PROSTATIC HYPERPLASIA
- Surgical management will increase
- Greater use of molecular profiling
- Dendreon Corporation
- GlaxoSmithKline Plc
- Hutchison 3G UK Limited
- Nymox Pharmaceutical Corporation
| Format | Properties | |
|---|---|---|
| Electronic (PDF) | The report will be emailed to you. The report is sent in PDF format. | This is a single user license, allowing one specific user access to the product. |
| Enterprisewide | The report will be emailed to you. The report is sent in PDF format. | This is an enterprise license, allowing all employees within your organisation access to the product. |
Note: Product cover images may vary from those shown
RELATED PRODUCTS
-
FROM -
Benign Prostatic Hyperplasia Global Clinical Trials Review, H2, 2011
- Published: August 2011
FROM -
Benign Prostatic Hyperplasia (BPH) Therapeutics - Pipeline Assessment and Market Forecasts to 2018
- Published: October 2011
FROM -
Urological Disorders Therapeutics to 2016 - Increasing Awareness and Aging Population will Drive the Benign Prostatic Hyperplasia and Urinary Incontinence Markets
- Published: August 2010
FROM -
The Drug Class Impact of Major Patent Expirations
- Language: English
- 52 Pages
- Published: March 2009
- Region: World
FROM -
DRG Insights: Benign Prostate Hyperplasia (G7)
- Language: English
- 53 Pages
- Published: May 2012
- Region: World
-
Benign Prostatic Hyperplasia and Male Lower Urinary Tract Symptoms (Event Driven)
- Language: English
- 156 Pages
- Published: November 2012
- Region: World
-
Benign Prostatic Hyperplasia - Pipeline Review, H2 2012
- Language: English
- Published: August 2012
FROM -
Benign Prostatic Hyperplasia Global Clinical Trials Review, H2, 2012
- Language: English
- Published: October 2012
FROM -
Global Benign Prostatic Hyperplasia Drug Pipeline Capsule - 2012 Update
- Language: English
- Published: September 2012
FROM
